NFE2L2 and non-small cell lung carcinoma: used next-generation sequencing (NGS) to analyze the tumor tissue of 1,391 patients with non-small cell lung carcinoma (NSCLC) and found that Keap1 mutations occurred in 11.3% (n = 157) and NRF2 mutations occurred in 3.5% (n = 49) of NSCLC patients (9).